Have you read the Bloomberg article about the opthamologist who billed Medicare for 21mill in 2012?
not sure a profit of 250 or so per test can be lined up against that
Printable View
Have you read the Bloomberg article about the opthamologist who billed Medicare for 21mill in 2012?
not sure a profit of 250 or so per test can be lined up against that
New Guy, Yeah you have completely missed the entire point of what i posted. Of course the numbers are not correct due to TVM and inflation. But thanks for your input. It was insightful
It’s both a market of stocks and a stock market. Aside from providing great buying opportunities, short term swings of IT stocks, up or down, really matters little, companies with good fundamentals will always outperform.
The Pacific Edge guidance is more positive than I suspect most short termers selling today recognise if they even know what the guidance is or where to find it, sales staff are increasing and management are suggesting that sales could be well ahead of the curve this calendar year, and it's reporting time soon.
It’s a gift even if you were to try and wrap it up in short term sentiment.
It's an historic industry average. At the moment, we sit well above that:
http://pages.stern.nyu.edu/~adamodar...le/psdata.html
and it's often meaningless because many biotechs have no sales:
http://www.investmentu.com/article/d...r#.U0eFqq2Sxt0
But margins aren't an issue in biotech. The problem lies with the products.